Search Videos and More
Symposium
ASH 2021 Highlights
Dana-Farber Cancer Institute faculty highlights from the 63rd Annual Meeting of the American Society of Hematology (ASH).
News
Scientists Identify Potential Target in Ewing Sarcoma Cells
Investigators led by Dana-Farber Cancer Institute’s Kimberly Stegmaier, MD, have discovered that knocking out a protein regulator in Ewing sarcoma cells causes the tumor cells to die from an overdose of a cancer-promoting protein.
News
Immunotherapy Combination Shown to Benefit Some Patients with Non-Small Cell Lung Cancer Resistant to Single Immunotherapy
A combination of two drugs that open the floodgates to an immune system attack on cancer curtailed tumor growth in some patients with non-small cell lung cancer (NSCLC) that was resistant to a single immunotherapy agent, results from a recent clinical trial show.
News
Venetoclax Added to Chemotherapy Improves Outcomes in Type of Leukemia
Adding the BCL-2 inhibitor drug venetoclax to a combination chemotherapy regimen significantly improved outcomes in Richter’s syndrome, a rare but deadly complication that develops in some patients with chronic lymphocytic leukemia (CLL), according to a study led by Dana-Farber investigators.
Symposium
San Antonio Breast Cancer Symposium (SABCS): December 2021
Dana-Farber Cancer Institute faculty highlights from the 2021 San Antonio Breast Cancer Symposium.
News
Immunotherapy Combination Shows Significant Benefit for Patients with Advanced Melanoma
A combination of two drugs that target different proteins on immune system T cells kept advanced melanoma in check significantly longer than one of the drugs alone in a phase 3 clinical trial involving 714 patients.
News
ASH 2021 Highlights - CME
Register for 2021 ASH Highlights CME
News
Study of Fully Vaccinated Patients with Cancer who had Breakthrough COVID-19 Shows 13% Mortality Rate
The first study to evaluate the clinical characteristics and outcomes of fully vaccinated patients with cancer who had breakthrough COVID-19 infections indicates they remained at high risk for hospitalization and death.
News
FDA Approval Offers Hope For Prevention of Acute Graft-Versus-Host Disease
Based on a clinical trial led by Leslie S. Kean, MD, PhD, of Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, the FDA has approved abatacept for the prevention of GVHD. This approval will allow many more patients to safely and effectively undergo stem cell transplants, particularly patients of diverse ethnicities who have more difficulty finding appropriately matched donors.
News
Drug Combination Found to Keep Chronic Lymphocytic Leukemia in Young Patients in Remission for Several Years
A new study by Dana-Farber Cancer Institute researchers suggests that a 2.5-year regimen involving ibrutinib and chemoimmunotherapy can provide deep, and lasting remissions for patients with chronic lymphocytic leukemia (CLL).
News
Molecular Analysis Advances Risk Profiling and Assessment of Immunotherapy Response in Smoldering Myeloma
Molecular and genetic research by scientists at Dana-Farber Cancer Institute has advanced the categorization of different risk groups in patients with smoldering myeloma, a premalignant condition that can – but doesn’t always – progress to the blood cancer, multiple myeloma.
News
American Society of Hematology (ASH) Annual Meeting
As leaders in blood and blood cancer research, physicians and scientists from Dana-Farber Cancer Institute shared advances and insights at the 63rd Annual Meeting of the American Society of Hematology (ASH) on December 11–14, 2021 in Atlanta, Georgia